Scholars Central

Conference abstractPublished 20 Jun 2016

Novel ayurvedic approach in the treatment of psychosis: An experimental study

Authors: Rajeeta Joseph, Gourav Deshmane, Asmita Wele, Madhuri Pawar, Vijaya Pandit

Bharati Vidyapeeth Deemed University, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Schizophrenia is a complex neuropsychiatric disorder with abnormalities involving multiple neurotransmitters like dopamine, serotonin, glutamate and GABA. Unmadgajakesari (UGK) is a herbomineral formulation claimed to possess antipsychotic activity. Hence the present study was carried out to assess the antipsychotic profile of UGK. Aim: To evaluate the antipsychotic activity of UGK in animal models. Materials & Method: After doing acute and sub-acute toxicity studies of UGK, it was evaluated for its effect on dopamine, serotonin, NMDA and GABA using following animal models: Inhibition of apomorphine induced climbing (dopamine), inhibition of 5-HTP induced head twitches (serotonin), Antagonism of MK-801 induced hyper locomotion (NMDA) in mice and Antagonism of PTZ induced convulsion (GABA) in rats. For studying each neurotransmitter, animals were divided into 6 groups, each group comprising of 6 animals. Group-I: Normal control, Group-II: Vehicle-control (ghrita), Group-III: Drug control (positive control). In test groups (IV-VI) UGK was administered in doses 100 mg/kg, 200 mg/kg and 400 mg/kg in mice and 70 mg/kg, 140 mg/kg and 280 mg/kg in rats. All the drugs were given orally for 8 days. Readings were taken on day 1and 8. Results: UGK was found to be non-toxic up to dose 2000 mg/kg. Significant antidopaminergic and NMDA activity was obtained on day 1 which reduced by 8th day. Anti-serotonergic activity found on day 1 and continued to be seen on day 8. GABAergic activity was not seen on day one but was present on day 8, more than anti-serotonergic action. GABAergic activity was seen only in low dose. Efficacy of UGK was not increased with dose increment. Conclusion: Present study concluded the multi-szte mechanism of UGK action in animal models of psychosis acting on dopamine, serotonin, NMDA and GABA receptors and activity changed over 8 days. GABA activity evolved over 8 days to become the major mechanism of action on long term use. None of the drugs presently available for the treatment of psychosis have such a changing profile and action on GABA.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmaceutical Care & Health Systems.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Care & Health Systems
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Rajeeta Joseph”
  • BylineArticles whose byline prints “Gourav Deshmane”
  • BylineArticles whose byline prints “Asmita Wele”
  • BylineArticles whose byline prints “Madhuri Pawar”
  • BylineArticles whose byline prints “Vijaya Pandit”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels